Page results
-
UCLH provides an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
We provide an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia. We provide an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia.
-
UCLH is considered a centre of excellence in the management of patients with Hodgkin’s and non-Hodgkin’s lymphoma.
-
The bone marrow transplant and haematopoietic stem cell transplant service at UCLH is the largest in Europe and provides a full range of transplant services.
-
UCLH is a designated Haemophilia Centre providing a 24/7 service for patients, including those needing treatment with blood products and clotting factor medications.
-
Thalassaemia is a group of inherited blood conditions where the part of the blood known as haemoglobin is abnormal.
-
Dr Tyagi is a consultant neuropsychiatrist with a special interest in Tourette's syndrome and obesessive compulsive disorders (OCD)
-
The UK Chagas Hub brings together healthcare professionals, researchers, advocates and members of the Latin American community to tackle Chagas disease in the UK and contribute to global efforts to eliminate the disease.
File results
-
FOI/2021/0330 - Sexual assault related incidents
-
FOI/2021/0332 - Trust Policy for Information Governance
-
FOI/2021/0333 - Mental health patient complaints
-
FOI/2021/0339 - Defibrotide for the treatment of hepatic veno-occlusive disease
-
FOI/2021/0341 - Total hospital deaths (all causes)
-
FOI/2021/0343 - Hospital admissions and deaths
-
FOI/2021/0345 - Maternity unit closures
-
FOI/2021/0349 - Cancer treatment
-
FOI/2021/0351 - Patients brought to A&E presenting complaint related to mental health
-
FOI/2021/0353 - Operational Pressures Escalation Levels (OPEL) Policy